Birgitta I Hiddinga

Dr. Birgitta I Hiddinga

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
BHBirgitta I Hiddinga
Birgitta I Hiddinga
JRJo Raskin
Jo Raskin
AJAnnelies Janssens
Annelies Janssens
PPPatrick Pauwels
Patrick Pauwels
JMJan P. van Meerbeeck
Jan P. van Meerbeeck
Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment remained relatively unchanged, with chemotherapy remaining the cornerstone of treatment. In this overview we will highlight the recent advances in the field of staging, surgery, radiotherapy and systemic treatment. Nevertheless, the prognosis remains dismal and there is a pressing need for new treatment options. We describe the progress that has been made in systemic treatment by repurposing existing drugs and the addition of targeted treatment. In recent years, immunotherapy entered the clinic with high expectations of its role in the treatment of SCLC. Unravelling of the genomic sequence revealed new possible targets that may act as biomarkers in future treatment of patients with SCLC. Hopefully, in the near future, we will be able to identify patients who may benefit from targeted therapy or immunotherapy to improve prognoses.

18 May 2018 in BMC Surgery
Verified
Journal Article
Open access
PDF file
MGMEDIASTrial study group
MEDIASTrial study group
JBJelle E. Bousema
Jelle E. Bousema
MDMarcel G.W. Dijkgraaf
Marcel G.W. Dijkgraaf
NPNicole E. Papen-Botterhuis
Nicole E. Papen-Botterhuis
HSHermien W. Schreurs
Hermien W. Schreurs
FBFrank J. C. van Den Broek
Frank J. C. van Den Broek
Background: In case of suspicious lymph nodes on computed tomography (CT) or fluorodeoxyglucose positron emission tomography (FDG-PET), advanced tumour size or central tumour location in patients with suspected non-small cell lung cancer (NSCLC), Dutch and European guidelines recommend mediastinal staging by endosonography (endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS)) with sampling of mediastinal lymph nodes. If biopsy results from endosonography turn out negative, additional surgical staging of the mediastinum by mediastinoscopy is advised to prevent unnecessary lung resection due to false negative endosonography findings. We hypothesize that omitting mediastinoscopy after negative endosonography in mediastinal staging of NSCLC does not result in an unacceptable percentage of unforeseen N2 disease at surgical resection. In addition, omitting mediastinoscopy comprises no extra waiting time until definite surgery, omits one extra general anaesthesia and hospital admission, and may be associated with lower morbidity and comparable survival. Therefore, this strategy may reduce health care costs and increase quality of life. The aim of this study is to compare the cost-effectiveness and cost-utility of mediastinal staging strategies including and excluding mediastinoscopy. Methods/design: This study is a multicenter parallel randomized non-inferiority trial comparing two diagnostic strategies (with or without mediastinoscopy) for mediastinal staging in 360 patients with suspected resectable NSCLC. Patients are eligible for inclusion when they underwent systematic endosonography to evaluate mediastinal lymph nodes including tissue sampling with negative endosonography results. Patients will not be eligible for inclusion when PET/CT demonstrates ‘bulky N2-N3’ disease or the combination of a highly suspicious as well as irresectable mediastinal lymph node. Primary outcome measure for non-inferiority is the proportion of patients with unforeseen N2 disease at surgery. Secondary outcome measures are hospitalization, morbidity, overall 2-year survival, quality of life, cost-effectiveness and cost-utility. Patients will be followed up 2 years after start of treatment. Discussion: Results of the MEDIASTrial will have immediate impact on national and international guidelines, which are accessible to public, possibly reducing mediastinoscopy as a commonly performed invasive procedure for NSCLC staging and diminishing variation in clinical practice. Trial registration: The trial is registered at the Netherlands Trial Register on July 6th, 2017 (NTR 6528).

25 January 2023 in Lung Cancer
Verified
Journal Article
Open access
BHBirgitta I Hiddinga
Birgitta I Hiddinga
DSDirk-Jan Slebos
Dirk-Jan Slebos
TKT. David Koster
T. David Koster
LHLucie B.M. Hijmering-Kappelle
Lucie B.M. Hijmering-Kappelle
THT. Jeroen N. Hiltermann
T. Jeroen N. Hiltermann
FBFrederike Bensch
Frederike Bensch
The number of solitary pulmonary nodules to be evaluated is expected to increase and therefore we need to improve diagnostic and therapeutic tools to approach these nodules. To prevent patients from futile invasive procedures and receiving treatment without histological confirmation of cancer, we evaluated the value of virtual bronchoscopy navigation to obtain a diagnosis of the solitary pulmonary nodule in a real-world clinical setting. In the NAVIGATOR single center, prospective, observational cohort study patients underwent a virtual bronchoscopy navigation procedure with or without guide sheet tunnelling to assess a solitary pulmonary nodule. Nodules were considered not accessible if a diagnosis could not be obtained by either by CT-guided transthoracic biopsy or conventional bronchoscopy. Between February 2021 and January 2022 35 patients underwent the virtual bronchoscopy navigation procedure. The overall diagnostic yield was 77% and was dependent on size of the nodule and chosen path, with highest yield in lesions with an airway path. Adverse events were few and manageable. Virtual bronchoscopy navigation with or without sheet tunnelling is a new technique with a good diagnostic yield, also in patients in whom previously performed procedures failed to establish a diagnosis and/or alternative procedures are considered not feasible based on expected yield and/or safety. Preventing futile or more invasive procedures like surgery or transthoracic punctures with a higher complication rate is beneficial for patients, and allowed treatment adaptation in two-third of the analyzed patient population.

19 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
HKHanneke Kievit
Hanneke Kievit
MMM. Benthe Muntinghe-Wagenaar
M. Benthe Muntinghe-Wagenaar
WAWayel Abdulahad
Wayel Abdulahad
ARAbraham Rutgers
Abraham Rutgers
LHLucie B. M. Hijmering-Kappelle
Lucie B. M. Hijmering-Kappelle
THT. Jeroen N. Hiltermann
T. Jeroen N. Hiltermann
Background: Tumor-infiltrating immune cells have been correlated with prognosis for patients treated with immune checkpoint inhibitor (ICI) treatment of various cancers. However, no robust biomarker has been described to predict treatment response yet. We hypothesized that the activation potency of circulating T cells may predict response to ICI treatment. Methods: An exploratory analysis was conducted to investigate the association between the response to immune checkpoint inhibition (ICI) combined with stereotactic radiotherapy (SBRT) and the potency of circulating T cells to be activated. Blood-derived lymphocytes from 14 patients were stimulated ex vivo with, among others, Staphylococcal enterotoxin B (SEB) and compared to healthy controls (HCs). Patients were grouped into responders (>median progression free survival (PFS)) and non-responders (<median PFS). The expression of the T cell activation marker CD69 and intracellular cytokines (IL-2, IFNγ, TNFα) in both CD4+ and CD8+ T cells in response to stimulation was measured using flow cytometry. In addition, serum levels of BAFF, IFNγ, and IL-2 receptor (sIL-2R) were measured by Luminex. Results: At baseline, a higher percentage of activated CD8+ T cells (15.8% vs. 3.5% (p = <0.01)) and IL-2+CD69+CD8+ T cells (8.8% vs. 2.9% (p = 0.02)) was observed in responders compared to non-responders upon ex vivo stimulation with SEB. The concurrently measured serum cytokine levels were not different between responders and non-responders. Conclusion: Baseline blood CD8+ T cell activation potency, measured by intracellular cytokine production after ex vivo stimulation, is a potential biomarker to discriminate responders from non-responders to SBRT combined with ICI.

1 June 2022 in Oncotarget
Verified
Journal Article
Open access
PDF file
BHBirgitta I Hiddinga
Birgitta I Hiddinga
KZKaren Zwaenepoel
Karen Zwaenepoel
AJAnnelies Janssens
Annelies Janssens
JMJan Van Meerbeeck
Jan Van Meerbeeck
PPPatrick Pauwels
Patrick Pauwels
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Birgitta Hiddinga1, Karen Zwaenepoel2, Annelies Janssens3, Jan Van Meerbeeck3 and Patrick Pauwels2 1 Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, The Netherlands 2 Department of Pathology, Antwerp University Hospital, Edegem, Belgium 3 Department of Pulmonology and Thoracic Oncology, European Reference Network for Rare or Low Prevalence Lung Diseases: ERN-LUNG, Antwerp University Hospital, University of Antwerp, Edegem, Belgium Correspondence to: Birgitta Hiddinga, email: b.i.hiddinga@umcg.nl Keywords: MGMT promoter methylation; anaplastic lymphoma kinase; neuroendocrine tumor; neuroendocrine carcinoma; small cell lung cancer Received: December 24, 2021 Accepted: May 07, 2022 Published: June 01, 2022 Copyright: © 2022 Hiddinga et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Background: Novel targets in neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) are needed to improve outcome. The presence of O6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation in NETs and NECs may act as a predictive marker for response on treatment with temozolomide. As anaplastic lymphoma kinase (ALK) plays an important role in the nervous system we hypothesized that ALK rearrangement can act as a biomarker in patients with NETs and NECs. Materials and Methods: We performed a retrospective analysis to establish the frequency of MGMT promoter methylation and ALK expression in tissue samples of patients with NETs and NECs. Results: 21% (14/67) of patients tested positive for MGMT promoter methylation. MGMT promoter methylation was present in 33% (3/9) patients with typical carcinoid, in 22% (2/9) patients with atypical carcinoid, in 22% (8/37) patients with small cell lung cancer and in 8% (1/12) patient with large cell neuroendocrine carcinoma. ALK- expression was present in 14% (10 of 70 patients). In all of these patients, no ALK-rearrangement nor ALK-mutation was revealed. Conclusions: Routine testing of NET and NEC samples for an ALK rearrangement is not recommended as ALK-expression is not associated with an ALK-rearrangement. Routine testing of NET and NEC samples for MGMT will detect a promoter hypermethylation in a sizable minority of patients who are eligible for a targeted treatment with temozolomide. <!--x2o[3d4443d7]-->

1 January 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
JMJan P. van Meerbeeck
Jan P. van Meerbeeck
LBLesley De Backer
Lesley De Backer
AJAnnelies Janssens
Annelies Janssens
BHBirgitta I Hiddinga
Birgitta I Hiddinga
GVGreetje Vanhoutte
Greetje Vanhoutte